BioStem Technologies (OTCMKTS:BSEM) Announces Earnings Results, Beats Estimates By $0.01 EPS

BioStem Technologies (OTCMKTS:BSEM – Get Free Report) posted its earnings results on Tuesday. The company reported 0.32 earnings per share (EPS) for the quarter, topping the consensus estimate of 0.31 by 0.01, Zacks reports. The company had revenue of 82.56 million for the quarter, compared to analysts’ expectations of 78.22 million.

BioStem Technologies Stock Down 25.5 %

BSEM traded down 5.95 during trading on Thursday, reaching 17.41. 257,100 shares of the company were exchanged, compared to its average volume of 33,599. The company has a market cap of $289.35 million, a price-to-earnings ratio of 26.46 and a beta of -0.36. BioStem Technologies has a 12-month low of 2.34 and a 12-month high of 28.26. The company’s 50-day moving average is 13.28 and its two-hundred day moving average is 10.64.

BioStem Technologies Company Profile

(Get Free Report)

BioStem Technologies, Inc, a life sciences corporation, focuses on discovering, developing, and producing pharmaceutical and regenerative medicine products and services. It develops various biologic stem cell based alternative products, as a treatment for ailments, such as joint pain, tendon and ligament injuries, neurodegenerative, and autoimmune diseases.

Featured Stories

• Five stocks we like better than BioStem Technologies
• Investing in Construction Stocks
• 3 GARP Stocks Offering Strong Growth: Aptiv, Allstate, Barrick
• Why Invest in High-Yield Dividend Stocks?
• Mouse Rising: The Iger Investment Pays Off for Disney Investors
• What is a Dividend Harvesting Strategy and How Can Investors Profit from it?
• Can CAVA Stock Be the Next Chipotle? Earnings Can Help